Literature DB >> 21356240

The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.

Ashley M Miller1, Foo Y Liew.   

Abstract

Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological effects of IL-33 are limited by a soluble decoy form of ST2 (sST2). Recent studies indicate a protective role for IL-33 and ST2L in atherosclerosis, obesity and cardiac remodeling. The present review summarizes currently available data showing the role for IL-33 and its receptor ST2L within cardiovascular disease, and the potential use of sST2 as a predictive cardiovascular biomarker.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21356240     DOI: 10.1016/j.pharmthera.2011.02.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  59 in total

Review 1.  Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2.

Authors:  Antonio J Vallejo-Vaz
Journal:  Eur Cardiol       Date:  2015-07

2.  Effects of interleukin-33 on cardiac fibroblast gene expression and activity.

Authors:  Jinyu Zhu; Wayne Carver
Journal:  Cytokine       Date:  2012-03-23       Impact factor: 3.861

Review 3.  Implications for Interleukin-33 in solid organ transplantation.

Authors:  Quan Liu; Hēth R Turnquist
Journal:  Cytokine       Date:  2013-03-27       Impact factor: 3.861

Review 4.  Emerging role of interleukin-33 in autoimmune diseases.

Authors:  Cheng Pei; Mark Barbour; Karen J Fairlie-Clarke; Debbie Allan; Rong Mu; Hui-Rong Jiang
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

5.  Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation.

Authors:  Heather M Perry; Stephanie N Oldham; Shawn P Fahl; Xuchu Que; Ayelet Gonen; Daniel B Harmon; Sotirios Tsimikas; Joseph L Witztum; Timothy P Bender; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-10       Impact factor: 8.311

6.  Soluble ST2: A Novel Prognostic Biomarker of Heart Failure.

Authors:  Ying-Chang Tung; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

7.  Antinociceptive and anti-inflammatory effects of 4-(arylchalcogenyl)-1H-pyrazoles containing selenium or sulfur.

Authors:  Daniela H Oliveira; Fernanda S S Sousa; Paloma T Birmann; Diego Alves; Raquel G Jacob; Lucielli Savegnago
Journal:  Pharmacol Rep       Date:  2020-01-09       Impact factor: 3.024

Review 8.  Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  Norihito Shimamura; Hiroki Ohkuma
Journal:  Transl Stroke Res       Date:  2013-11-20       Impact factor: 6.829

9.  Soluble ST2 predicts elevated SBP in the community.

Authors:  Jennifer E Ho; Martin G Larson; Anahita Ghorbani; Susan Cheng; Ramachandran S Vasan; Thomas J Wang; James L Januzzi
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

10.  IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Hui Xuan Lim; Seulah Choi; Daeho Cho; Tae Sung Kim
Journal:  Immunol Cell Biol       Date:  2016-08-10       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.